Handheld biosensor offers instant test results for bladder cancer
This article was originally published in Start Up
A handheld biosensor in development by PhageTech Inc. is designed to detect the presence of several biomarkers associated with the recurrence of bladder cancer from a small urine sample, without the need for expensive and time-consuming lab-based tests. The device could also monitor treatment.
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.